Two more recent studies have demonstrated that TRIM31 alleviates NAFLD and NASH pathologies by targeted degradation of rhomboid 5 homolog 2 (Rhbdf2) (35) and TAK1 (36) in the liver. This evidence concerns the gene TRIM31 and metabolic dysfunction-associated steatohepatitis.